Clinical characteristics and prognostic analysis of newly diagnosed CD5-positive diffuse large B-cell lymphoma
10.3760/cma.j.cn115356-20220712-00202
- VernacularTitle:初诊CD5阳性弥漫大B细胞淋巴瘤患者临床特征及预后分析
- Author:
Yuhong TANG
1
;
Jiajia LIU
;
Yang SI
;
Yuli WANG
;
Yanfang ZHANG
;
Rong WEI
Author Information
1. 同济大学附属第十人民医院血液科，上海 200072
- Keywords:
Lymphoma, large B-cell, diffuse;
CD5 antigen;
Disease attributes;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2023;32(9):520-523
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics and prognosis of newly diagnosed CD5-positive diffuse large B-cell lymphoma (DLBCL).Methods:The clinical data of 19 newly diagnosed CD5-positive DLBCL patients in Tenth People's Hospital of Tongji University and Ninth People's Hospital of Shanghai Jiao Tong University School of Medicine between January 2015 and December 2018 were retrospectively analyzed. Their clinical characteristics and laboratory indexes were observed; Kaplan-Meier method was used for survival analysis, and Cox proportional risk model was used to make multifactor analysis of the prognostic factors.Results:The median age of 19 newly diagnosed CD5-positive DLBCL patients was 63 years (34-76 years). All 19 patients included 13 cases with Ann Arbor Ⅲ-Ⅳ stage; 12 cases with lactate dehydrogenase higher than the normal value limit, 9 cases with international prognostic index scores ≥ 4, 13 cases with B symptoms, 10 cases with Ki-67 positive index ≥ 80%, 15 cases with more than 1 lymph extra nodal organ involvement and 8 cases with tumor mass (mass diameter ≥ 7 cm). The 2-year progression-free survival (PFS) rate was 47.4% and 2-year overall survival (OS) rate was 63.2%. Univariate analysis showed that Ann Arbor stage, tumor mass, lymph extra nodal involvement and ≥ 4 courses of intrathecal injection were associated with OS (all P < 0.05). Multivariate analysis showed that Ann Arbor stage (stage Ⅰ-Ⅱ vs. stage Ⅲ-Ⅳ: HR = 0.158, 95% CI 0.031-0.803, P = 0.026), tumor mass (tumor diameter < 7 cm vs. tumor diameter ≥ 7 cm: HR = 0.076, 95% CI 0.009-0.637, P = 0.018)and ≥ 4 courses of intrathecal injection (yes vs. no: HR = 9.130, 95% CI 1.062-78.157, P = 0.044) were independent influencing factors for OS. Conclusions:Newly diagnosed CD5-positive DLBCL is highly aggressive and susceptible to extra nodal infiltration. Ann Arbor stage Ⅲ-Ⅳ, tumor mass, and not receiving ≥ 4 courses of intrathecal injection are independent risk factors affecting the prognosis of CD5-positive DLBCL patients.
